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Abstract
Delineating the genetic causes of developmental disorders is an area of active investigation. Mosaic structural abnormalities,
deﬁned as copy number or loss of heterozygosity events that are large and present in only a subset of cells, have been detected
in 0.2–1.0% of children ascertained for clinical genetic testing. However, the frequency among healthy children in the
community is not well characterized, which, if known, could inform better interpretation of the pathogenic burden of this
mutational category in children with developmental disorders. In a case–control analysis, we compared the rate of large-scale
mosaicism between 1303 children with developmental disorders and 5094 children lacking developmental disorders, using an
analytical pipelinewe developed, and identiﬁed a substantial enrichment in cases (odds ratio = 39.4, P-value 1.073e− 6). Ameta-
analysis that included frequency estimates among an additional 7000 children with congenital diseases yielded an even
stronger statistical enrichment (P-value 1.784e− 11). In addition, tomaximize the detection of low-clonality events in probands,
we applied a trio-basedmosaic detection algorithm, which detected two additional events in probands, including an individual
with genome-wide suspected chimerism. In total, we detected 12 structural mosaic abnormalities among 1303 children (0.9%).
Given the burden ofmosaicism detected in cases, we suspected thatmany of the events detected in probands were pathogenic.
Scrutiny of the genotypic–phenotypic relationship of each detected variant assessed that the majority of events are very likely
pathogenic. This work quantiﬁes the burden of structural mosaicism as a cause of developmental disorders.
Introduction
Developmental disorders (DD) are diseases of impaired prenatal
development and arise from several genetic mechanisms. The
most common mutational category reported in children with
DD is de novo mutations (1,2). De novo mutations that occur
post-zygotically result in genetically heterogeneous cellular po-
pulations, a phenomenon known as mosaicism. As mutations
arise with every cell division, strictly speaking, all humans are
mosaic. Nevertheless, physiology-disruption (pathogenic) mo-
saicism is more likely to occur from high-frequency mutations,
and here we focus on abnormalities with sufﬁcient cellular fre-
quency to be detected by currentmicroarray technology. Another
cause of genetically distinct cell populations, although much
rarer, is chimerism, owing to the fusion of cell lineages from dif-
ferent zygotes (3). The detection sensitivity of mosaic abnormal-
ities is a function of several parameters, some of which are
intrinsic to the mosaic event—including event size, clonality,
type (loss, gain, and LOH); others which are technology depend-
ent—including platform (karyotyping or microarray), company,
number of probes, signal-to-noise ratio of probes; and others
which are algorithmic—such as single-sample versus trio-
based tests. In this study, we primarily focus on large mosaic
abnormalities in at least ∼10% of cells using single-nucleotide
polymorphism (SNP) microarray and single-sample tests.
Mosaicism can involve multicellular clonality for mutations
of any size (3,4). While the detection of mosaic point mutations
has been used for the validation of suspected mosaicism at spe-
ciﬁc genomic positions in rare disease and cancer (5,6), reliable
detection of small-scale mosaicism genome wide requires very
high-depth whole-genome sequencing, which is not currently
economical for widespread clinical application. At the other
end of the size continuum, cytogenetic karyotyping has been
used for decades in a clinical diagnostic setting to detect micro-
scopically visible (5–10Mb or larger) abnormalities, including
mosaic events, in children with congenital disorders. While
karyotyping is still widely used in many centres, this approach
is insensitive to sub-microscopic rearrangements and super-
numerary marker chromosomes (7) and is labour-intensive, be-
cause, for example, 30 cells must be counted to exclude 10%
mosaicismwith 95% conﬁdence (8). Compared with karyotyping,
SNP genotyping chips offer a higher-resolution, higher-through-
put assay and are considered a standard of care for clinical
diagnostics in children with developmental disabilities (9). The
resolution of SNP chips for mosaicism detection is inﬂuenced
by probe density and the signal-to-noise ratio of the experiment
and the type ofmosaic abnormality. In this study, we focussed on
mosaic events of at least 2 Mb in size, a generally accepted
threshold for large structural alterations (10), allowing a fair
basis of comparison for the different chip designs we analysed,
and concordant with a recent study that used an SNP chip design
and algorithmic protocol similar to our own (11). Henceforth, the
termmosaicismwill refer to mosaic events of at least 2Mb in size.
The SNP platform generates ameasure of allelic intensity, the
log R ratio (LRR) and a measure of allele balance, the B-allele fre-
quency (BAF). When genetic heterogeneity exists in assayed cell
populations, the BAF will be skewed from expected diploid fre-
quencies, and software tools translate deviation of BAF into mo-
saic detections. Mosaic Alteration Detection (12) (MAD), is a
popular software tool that detects deviations in BAF, groupsnear-
by segments into clusters and uses a statistical test to determine
clusters that are statistically unlikely at a given signiﬁcance
threshold. Once such clusters are selected, the average LRR
value in each segment is used to classify segments into mosaic
type: loss, gain or loss of heterozygosity (LOH). The detection sen-
sitivity for MAD on SNP chips with ∼1million probes for events at
least 2Mb in size is limited to loss or LOH events in ∼10–90% of
cells and gain events in ∼20–80% of cells (11,12). Detection
power can be improved if phased genotype data are available,
as it can then be shown that adjacent deviations in BAF arise
from the same haplotype, which is less likely by chance alone.
triPOD (13) is a trio-based mosaic detection tool that leverages
parental genotype data to phase child genotypes and has been
shown to have increased sensitivity, compared with MAD, for
detecting events below ∼10% clonality, but this software tool
requires parent genotype data, which are not always available.
MADwas recently implemented on ∼60 000 adults and identi-
ﬁed a strong positive correlation between the age of the sampled
individuals and mosaicism frequency (11). Several studies have
measured mosaicism frequency among children ascertained for
clinical diagnostic testing (Table 1) and have derived estimates
from ∼0.2–1%. In comparison with studies of clinically ascer-
tained children with DD, the prevalence of mosaicism among
children without DD is less well established, although evidence
suggests that the frequency is extremely low (11,19). In the cohort
studies analysed by Laurie, no mosaicism was detected in any of
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1600 individuals aged 10–19 years. While 13 mosaic events were
found among 6810 children aged 0–4, a frequency of 0.19%, this
may reﬂect ascertainment bias, as the youngest stratum of chil-
dren in this study included children from a cohort study of oral
clefts, a potential manifestation of pathogenic mosaicism.
Thus, the frequency of mosaicism in children without DD re-
mains an open question.
In this study, to quantify the burden of pathogenic structural
mosaicism in childrenwith DDs, we determined the frequency of
structural mosaicism in thousands of children with and without
DD, using both single-sample (MAD) and trio-based (triPOD) de-
tection of structural mosaicism from SNP chip data. Both clinical
review of the speciﬁc variants and a statistical analysis of enrich-
ment of structuralmosaicism in cases indicated that themajority
of the mosaic events detected in probands were pathogenic.
Results
To estimate the frequency of structural mosaicism in children
with and without DD, we compiled SNP genotyping data on
DNA from blood or saliva from three studies: a trio-based study
of children with DD, the Deciphering Developmental Disorders
(DDD) study (N = 1303) (20); two UK birth cohort studies: the
Avon Longitudinal Study of Parents and Children (ALSPAC,
N = 2168) (21) and the Twins Early Development Study (TEDS,
N = 3588) (22). In case–control analyses based on single-sample
detection of structural mosaicism (using the MAD algorithm),
we compared DDD cases with a control set that included ALSPAC
and TEDS children lacking delayed development.
Additionally, we implemented trio-based detection of struc-
tural mosaicism (using the triPOD algorithm), using two studies
with trio data available: DDD, and the Scottish Family Health
Study, a study of young-adult healthy controls and their parents
[Scottish Family Health Service (SFHS), N = 478] (23).
Below we describe the pipelines we developed to detect and
ﬁlter candidate mosaic events, and then we characterize themo-
saic events detected in probands and their likely clinical signiﬁ-
cance (Fig. 1).
Mosaic detection workﬂow
Initial testing of MAD on DDD study data produced >1000, mostly
spurious, putative structuralmosaic events. The predominant re-
current source of these erroneous signals was due to incorrect
classiﬁcation of long tracts of constitutive homozygosity as
being mosaic; such homozygous tracts are relatively frequently
observed in theDDD studyas families often have familial related-
ness (24), which results in large blocks of inherited homozygosity
(identity by descent). Moreover, excess putative detections fre-
quently arose from over-segmentation of single contiguous
regions, an artefact of imperfect delineation of event boundaries
that is a common pitfall for segmentation algorithms. A smaller
number of putative mosaic detections arose from misclassiﬁca-
tion of constitutive copy number events, mainly duplications,
as being mosaic. These CNVs had extreme B-allele deviations
and LRR values that clustered with inherited duplications and
not with other de novo mosaic events, supporting the classiﬁca-
tion of these events as constitutive (Supplementary Material,
Fig. S1, Supplementary Material, DDD & SFHS Constitutive CNV
Filtering).
Automatic ﬁltering (Materials and Methods) based on the
common error modes described earlier reduced the number
of putative detections by ∼90%, to a manageable number that
could be manually reviewed. Manual curation was then used to
ﬁlter putative detections resulting from stochastic ﬂuctuations
in the data. To avoid unintentional exclusion of mosaicism,
samples were not automatically excluded on the basis of aber-
rant average standard deviation of heterozygous B-allele fre-
quencies, a commonly employed QC criterion in GWAS studies;
Table 1. Clinical diagnostic microarray studies of children with congenital or developmental abnormalities
Platform No. of probes Tissue No. samples No. mosaics Frequency (%)
Bruno Illumina HumanCytoSNP-12 220 k Blood, skin biopsy and saliva 5000 13 0.26
Conlin IlluminaQuad610 (SNP) 620 k Blood and ﬁbroblasts 2019 23 (1 chimera) 1.1
Ballif SignatureChip CGH 969 BACs Blood 3600 18 0.5
Cheung CGH 853 BACs Blood 2585 18 0.5
Pham BCM V8 OLIGO (aCGH) 180 k Blood 10 362 57 0.55
SNP, single-nucleotide polymorphism; aCGH, array comparative genomic hybridization; BACs, bacterial artiﬁcial chromosomes; (14–18).
Figure 1. Overview. A MAD-based workﬂow was used to detect mosaicism. This workﬂow identiﬁed an enrichment of mosaicism in cases compared with controls, and
triPOD detected two additional mosaic events not detected by MAD. Clinical assessment was performed on all 12 probands of the DDD study with mosaicism.
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eight samples with consistent multi-band skew of BAFs across
all chromosomes, a signature of contamination, were removed
from analysis (Supplementary Material, Fig. S1). However,
this strategy also retained one sample with a high BAF standard
deviation of 0.06 and which reﬂected a real mosaic structural
event.
To assess the accuracy of this MAD-based workﬂow, we
compared the frequency of mosaic events detected among the
parents of the DDD and SFHS trio studies with established esti-
mates of mosaicism frequency for individuals of these ages.
The median age at sampling of DDD parents was 39 and that of
SFHS parents was 59 (Fig. 2). We identiﬁed 6 mosaic events
among 955 parents of SHFS controls, a frequency of 0.6%, and 4
among 2356 parents of DDD probands, a frequency of 0.1%,
which are within the conﬁdence interval estimates for these
ages (11) (Fig. 3). This suggested that the method, ﬁltering
strategy and manual curation used were not inconsistent with
expectations, and we next used this workﬂow to detect mosai-
cism in the child samples.
Estimates of mosaicism frequency in cases and controls
We assessed the frequency of mosaic events in the DDD cases,
and in the controls of TEDS, ALSPAC using SNP chip data.
Among 1303 children from theDDDstudy, therewere 10withmo-
saic events, a rate of 0.77% (Figs 4 and 5). Compared with the
estimate of mosaicism detected among children ascertained for
genetic testing in Conlin et al., the frequency of mosaicism in
DDD was not signiﬁcantly different (Fisher exact test two-sided,
P-value 0.4698). The range of cellular fraction (clonality) was 23–
66%. We investigated the distribution in saliva and blood of the
eight mosaic copy number events with validation data available,
ﬁnding that two were present in both saliva and blood, six were
present in saliva but not blood and no events were present in
blood alone.
There were 3588 children in the TEDS cohort with genotype
data from blood DNA available. Analysis was performed on
2926 samples for which phenotypic datawere available and sam-
ples were not medically excluded nor had developmental pro-
blems. There were zero mosaic events retained after accounting
for seven constitutive detections (Supplementary Material,
Computational Filtration). There were 8970 children in ALSPAC
with genotype data available from DNA derived from blood or
cell lines. An initial attempt at detecting mosaicism in data
from both DNA sources detectedmoremosaicism in samples de-
rived from cell lines (two-sided Fisher exact test P-value 5e− 05),
suggesting the presence of cell-line-induced chromosomal rear-
rangements (25,26), whichwould overestimate in vivomosaicism.
To assess frequency in children accurately, we analysed the 3290
DNA samples sourced from only blood or saliva (but not cell
lines). Of 2538 children with phenotypic data available, 2168
(85%) lacked DD or major developmental problems. One sample
contained a mosaic LOH, representing a frequency of 0.05%.
We also investigated a collection of 478 individuals from the
SFHS. These were samples without DD recruited in early adult-
hood, median age 31. There were zero mosaic events remaining
after automated ﬁltering and manual curation of 28 possible
mosaic events.
Figure 2. The (A) sample number and (B) ages corresponding to the analysed studies.
Figure 3. The frequency of mosaicism detected in the parents of the trio cohorts
was within the conﬁdence intervals of the frequency detected for samples of this
age range.
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Figure 4. (A) The percentage of samples with mosaic events in the case and control cohorts. (B) A depiction of each mosaic event, where the line segments represent the
ideal location of mosaicism for gains (blue), LOH (orange) and losses (red).
Figure 5. All Proband Detections: The detections made by (A) MAD & triPOD, (B) by MAD alone and (C) by triPOD alone.
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Compared with the fraction of mosaic detections among all
child control samples (2 in 5345), the frequency of mosaicism in
DDD probands (10 in 1303) was highly statistically signiﬁcant
(odds ratio 20.66, one-sided Fisher exact test, P-value 3.627e− 6).
A meta-analysis additionally incorporating 7119 samples from
twoprevious studies (15,17) strongly supports a statistical enrich-
ment of mosaicism in children with DD (P–value, 9.919e − 11).
Before assessing the pathogenicity of these mosaic detections,
we ﬁrst attempted to detect additional lower-clonality mosaic
events using a trio-based detection tool.
Additional detections using triPOD
A recent trio-based algorithm, triPOD, has been shown to have
improved sensitivity to detect lower-clonality mosaic events
compared with MAD (13) by leveraging haplotype information
in trio data. We implemented this tool on DDD trio data to im-
prove detection of mosaic events of lower clonality. Complete
trio genotypes were available for 1082 of 1303 (83%) probands,
and thesewere processed with triPOD. Therewere a vast number
(4920) of putative detections, of which 148 were at least 5Mb and
876 were at least 2Mb. We manually reviewed all events at least
5Mb and analysed the subset of those at least 2Mb with a non-
zero median BAF deviation (see Materials and Methods). Detec-
tion at the 2-Mb level identiﬁed 7 of the 10 mosaic events that
had been detected in single-sample analysis by MAD. Two of
the three remaining events lacked complete trio data so they
could not be analysed by triPOD. The third remaining undetected
event was a mosaic duplication characterized by an additional
haplotype not present in the diploid cell line (Fig. 5; Supplemen-
tary Material, Fig. S2).
An additional two events were identiﬁed among the 148
putative events of >5Mb detected by triPOD that were each re-
viewed manually (Fig. 5). One event appeared to have a chromo-
some-wide elevation of LRR and a BAF pattern reﬂecting meiotic
crossover, perhaps resulting from incomplete trisomy rescue.
The second event was extraordinary for a genome-wide pattern
of large segments of consistently aberrant BAF interspersedwith
segments of normal BAF. These segments of aberrant BAF were
present on most chromosomes in three or fewer large segments
per chromosome. We investigated the parental origin of these
aberrant BAF segments by plotting the proband BAFs within
these segments separately for each conﬁguration of parental
genotypes (SupplementaryMaterial, Fig. S3). The siteswith aber-
rant BAFwere only observedwhere the father was heterozygous,
suggesting that the aberrant BAFwas due to the presence of both
paternal chromosomes. In addition, the BAF at obligate hetero-
zygous sites in the proband (parents homozygous for different
alleles) was always skewed towards a greater contribution from
the inherited paternal allele, suggesting a second paternal
haplotype, and only one maternal haplotype. These observa-
tions are potentially compatible with a triploid cell line; how-
ever, karyotypic analysis failed to identify any triploid cells. An
alternative explanation is ‘androgenetic/bipaternal mosaicism
or chimerism’ (27,28), which occurs with fusion of a fertilized
embryo and a polar body fertilized by a second sperm that
undergoes endoreduplication. The homozygous BAF skews had
BAF deviations consistent with approximately 15% clonality,
which is a smaller cellular burden than any event detected by
MAD.
triPOD was also applied to detect structural mosaicism
in the 475 SFHS control trios, but zero mosaic detections were
uncovered following computational ﬁltering and manual
curation.
Clinical interpretation of probands with mosaicism
Mosaicism was detected in twelve individuals with DD (Table 2).
For each proband, we collected data for the perinatal period,
assessed developmental milestones and recorded phenotypes
at the time of recruitment using a standardized nomencla-
ture called the Human Phenotype Ontology (29). We assessed
whether each mosaic event overlapped with regions implicated
in speciﬁc genomic disorders and, if so, assessed the concord-
ance of patient phenotypeswith themanifestations of these gen-
omic syndromes. To identify a relationship between the mosaic
copy number events found in probands to CNVs listed in public
databases required the assumptions that: (1) pathogenicity is
due to disruption of overlapped regions, not owing to disruption
of boundary elements for which the compared CNVs may differ,
and (2) constitutive CNVs that are pathogenic produce pheno-
types which are similar in character, if perhaps larger in magni-
tude than the corresponding CNV in mosaic state. We presumed
that mosaic LOH mutations might result in imprinting syn-
dromes, by disrupting differentially methylated regions (30) or
manifest recessive diseases, by converting a single inherited
deleterious allele to homozygosity. To investigate these possibil-
ities, we used the proband BAF and parental genotypes to deter-
minewhich proband allele was present in a homozygous state in
the tissue containing the mosaic abnormality.
Patient 260462 had global developmental delay, intermittent
horizontal nystagmus with alternating abnormal head position
and bilateral, symmetric large optic nerves. Magnetic resonance
imaging of the brain showed cortical atrophy, generalized delay
in myelination, moderate-sized left middle cranial fossa, arach-
noid cyst and deﬁciency of the rostrum of corpus callosum and
atrophic splenium. Copy number analysis by karyotype and
aCGH, genetic testing for Pitt–Hopkins, Fragile X syndrome,
MECP2 gene test, spinal muscular atrophy and Angelman
syndrome were all normal. Upon recruitment to the DDD study,
aCGH was performed on blood and saliva, and no large (>500 kb)
CNVs were reported. Our mosaic analysis on SNP data from a
salivary sample identiﬁed three mosaic events on chromosome
18, two deletions and one duplication in ∼50% of cells. Results
from triPOD showed that the deletions resulted from loss of the
maternal allele, while the duplication was of the paternal allele
(Supplementary Material, Fig. S4). Fluorescent in situ hybridiza-
tion (FISH) analysis on cells from a buccal sample conﬁrmed
these events in 56 of 100 inspected cells. Retrospective scrutiny
of the salivary CGH array identiﬁed deviations in aCGH probes
but insufﬁcient to be detected by the standard copy number de-
tection pipeline. No deviation in blood aCGH probes was noted,
suggesting the mosaicism was not present in all tissue types,
and providing a likely explanation as why genetic testing, per-
formed on blood, was negative. Themosaic deletion on chromo-
some 18 contains the gene TCF4, mutations in which cause
Pitt–Hopkins syndrome (31), a diagnosis previously considered
in this child, and the diagnosis was conveyed to the family.
Female patient 261240 required 7 days in neonatal intensive
care and 2weeks with nasogastric feeding. She had developmen-
tal delay, seizures and short stature (154 cm, third centile at 16
years). Before enrolment into DDD, clinical karyotyping was per-
formed on blood and showed a marker chromosome originating
from chromosome 5, local inspection by aCGH did not detect any
CNVs and the marker chromosome was classiﬁed as a balanced
rearrangement. Clinical testing for Fragile X syndrome was nor-
mal. Our mosaicism analysis was performed on a saliva sample
and identiﬁed a 22-Mb duplication, present in ∼40% of assayed
salivary cells. Review of the interphase karyotypic data noted
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that the suspected marker chromosome contained a double-ring
chromosome. Retrospectivemanual review of the array CGHdata
on saliva identiﬁed stretches of raised LRR probes. Therefore, this
event was classiﬁed as present in both blood and saliva. Duplica-
tions in this region, 5q23.2 to 5q32, have been previously impli-
cated in seizure disorders [p.252] (32) and shared phenotypes
and short stature are seen in a different patient with an overlap-
ping duplication in the Decipher database (255372). Therefore,
this mosaic aberration was considered very likely pathogenic.
Female patient 258956 had a number of congenital abnormal-
ities, including a sacral meningocele, polydactyly, bilateral tali-
pes, atrial and ventricular septal defects, pulmonary stenosis,
EEG epileptiform activity, facial asymmetry, hirsuitism and
hypomelanosis of Ito. At birth, she required neonatal intensive
care for apnoea and nasogastric feeding for 10 days. Clinical
aCGH (Agilent 8 × 60 K oligoarray) testing performed on blood
was normal. The DDD aCGH results from blood and saliva
showed upward deviation in the data from assayed saliva tissue,
only. Our mosaicism analysis on saliva identiﬁed a 44-Mb dupli-
cation on chromosome 3q in ∼55% of assayed cells. Thus, it is
likely that this event is tissue-limited. Duplications of 3q are as-
sociated with joint contractures, talipes, feeding difﬁculties, hir-
suitism and heart defects, including ASD and VSD (33). There are
several patients also present in the DECIPHER databasewho have
duplications overlapping this large duplication in the child,
including 280 551, with hirsuitism, feeding difﬁculties and
global developmental delay; 283 584, with sacral dimple and
low set ears; 1561, with frontal bossing and sacral dimple. Several
examples of duplications of 3q have meningocele [p.145] (32).
Given the consistency of phenotypes with the proband and
these patients, the mosaic mutation was considered very likely
pathogenic.
Female patient 261373 had intrauterine growth retardation
with a birth weight of 2.0 kg (ﬁrst centile). She had moderate de-
velopmental delay, severe speech delay, a high-archedpalate and
prognathism. An array on blood lymphocyteswas performed and
identiﬁed no abnormalities. Our SNP mosaicism analysis on sal-
iva identiﬁed a gain of 12p in an estimated 44% of assayed cells,
suggesting tissue-speciﬁcmosaicism as the cause. The eventwas
detected also by conﬁrmatory aCGH from saliva, and interphase
FISH on buccal DNA of 100 cells identiﬁed a triplication of 12p in
12% of cells. Triplications of 12p (tetrasomy 12p) are the cause of
the clinical syndrome known as Pallister–Killian mosaic syn-
drome (34), which is consistent withmany of her phenotypic fea-
tures and the diagnosis was conveyed to the family.
Patient 263654 required 19 days of neonatal intensive care to
manage respiratory distress, jaundice and hypoglycaemia. His
speech and languagewere delayed, and anMRI identiﬁed inferior
vermis hypoplasia. Fragile X testing was normal. Our aCGH was
performed on blood and was normal. Our SNP mosaicism ana-
lysis identiﬁed a 4-Mb duplication in ∼33% of salivary cells. The
BAF pattern of the duplication was consistent with a meiotic ori-
gin of the duplication in the trisomic cell line. FISH was per-
formed on blood and buccal tissues, and the event was
detected in buccal tissue only, in 25 of 50 examined cells. As
only interphase FISH was available for buccal tissue, positional
information for the additional allele was not possible. The impli-
cated region overlaps most of 16p11.2, a cytogenetic region in
which duplications arewell known to cause disruption of speech
and language development (35), and this event was considered
very likely pathogenic.
Patient 259003 had global developmental delay, no speech
and generalized hypotonia. Clinical aCGH (6K BAC array) and
testing for Angelman syndrome were normal. Our SNP mosaicT
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analysis on salivary cells identiﬁed a 5-Mb deletion in 54% of cells
at chromosome 22q, from 22q13.31 to 22qter. Array CGH results
showed a slight negative deviation in both blood and saliva
probe data, but not detected by the aCGH algorithm. FISH on
blood lymphocytes identiﬁed the event in 43 of 100 of blood
cells. This region overlaps with the well-characterized 22q13
Deletion syndrome, also known as Phelan–McDermid syndrome,
which has as its main characteristics global developmental
delay, absent or severely delayed speech and hypotonia; these
manifestations are consistent with child phenotypes (36) and
the mosaic event was considered very likely pathogenic.
Patient 260108 had truncus arteriosis, hypertelorism and
feeding difﬁculties at birth. She demonstrated global develop-
mental delay and required nasogastric feeding. An MRI was ab-
normal and showed possible arterial shunting. Clinical testing
for SALL1, SALL4, CHD7 and Prader–Willi syndrome were normal.
Our aCGH data in blood showed no abnormalities. Our SNP mo-
saic analysis identiﬁed a 14-Mb duplication on chr17 in ∼45% of
assayed saliva cells, conﬁrmed by aCGH on saliva (6K BACK
array). This mutation appears to be tissue limited. FISH valid-
ation was not possible. Mosaic trisomies of chromosome 17 are
associated with substantial heart defects, including truncus ar-
teriosus and Tetralogy of Fallot, as well as speech delay (37), con-
sistent with phenotypes in the proband, and considered the
likely cause of disorder.
Patient 263708 requiredneonatal intensive carewith nasogas-
tric feeding. At delivery, the placenta was hypertrophic, and nu-
merous haemangiomata were noted. She had macroglossia,
macrocephaly and hepatic haemangiomata, as well as episodic
hypoglycaemia, oligodontia, esotropia and gynecomastia. The
patient had pigmentary mosaicism following Blashko’s lines.
Clinical karyotypewas normal. Beckwith–Wiedemann syndrome
was suspected, but clinical testing was negative. Our analysis of
SNP data for mosaicism identiﬁed genome-wide skews of BAFs,
believed to reﬂect a cell line with unipaternal disomy (Fig. 5C).
Some ten or so examples of genome-wide unipaternal disomy
have now been reported, with different underlying mechanisms
(27). The dominant manifestation of unipaternal disomic mosai-
cism is Beckwith–Wiedemann disorder, which is consistent with
the majority of the phenotypes in this case. In addition, because
Beckwith–Wiedeman is associated with increased tumour risk,
this diagnosis can help increase surveillance of tumour develop-
ment through increased screening (38). Given the overlap of phe-
notypes known in genome-wide paternal UPD and the child’s
phenotypes, the variant was considered very likely pathogenic.
Patient 258190 required 7 days of neonatal intensive care
owing to hypoglycaemia and macrosomia (birth weight and
head circumference >99th centile). Congenital muscular torticol-
lis, partial cryptorchidism and vertebral abnormalities ( joint fu-
sions in cervical spine) were noted. He had global developmental
delay, and autism. Our aCGH assay was performed on blood and
was negative, and our mosaic SNP analysis on saliva using MAD
was negative. Analysis using triPOD on saliva detected a low-
level trisomy on chromosome 20. FISH conﬁrmed trisomy in
30% of cells from buccal sampling but absent in cells from lym-
phocytes, suggesting themutation is likely tissue limited. Mosaic
trisomy 20 syndrome includes head tilt, developmental delay,
autistic features, spinal and genital abnormalities (39), all pheno-
types consistent with those observed in this patient; therefore,
the mosaic event was considered very likely pathogenic.
Patient 259709 required neonatal intensive care for 31 days
with enteral feeding. Developmental milestones were delayed:
sitting independently was achieved at 23 months and walking in-
dependently beganat 3 years. At recruitment, recordedphenotypes
included joint laxity, hyperextensible skin, anterior ‘beaking’ of
lumbar vertebrae and delayed speech and language development.
Our analysis of SNP data identiﬁed a chromosome-wide LOH on
chromosome 14 in ∼65% of assayed salivary tissue. Informative
parental genotypes overlapping the mosaic region identiﬁed that
the LOH resulted from amosaic loss of thematernal allele (Supple-
mentaryMaterial, Fig. S5). Loss of heterozygositymay be pathogen-
ic by causing imprintingdisorders or by inheritance of a deleterious
variant, present from a carrier parent, to homozygosity. Constitu-
tive UPD 14 maternal is known to cause Temple syndrome, for
which feeding difﬁculties at birth, joint laxity and developmental
delayare present (40). These features are consistentwith the child’s
phenotypes and considered very likely pathogenic.
Patient 257978 had thoracolumbar scoliosis, seizures, somno-
lence and abnormality of neuronal migration. She demonstrated
profound intellectual disability and achieved no developmental
milestones. Clinical karyotyping and telomeric MLPA were
normal. Our SNP mosaicism analysis identiﬁed an 80-Mb loss-
of-heterozygosity region on chromosome 5 in 24% of assayed
salivary cells. We suspected that conversion to homozygosity of
a deleterious variant in the LOH region may underlie the patho-
genicity. To investigate this, from exome sequence data, we
inspected rare (<0.5% minor allele frequency) variants that led
to missense and loss of function mutations in genes overlapping
the LOH region. Of seven such variants, themost interesting can-
didate was a missense variant in N4BP3, a gene recently reported
to be required for normal neuronal axonal branching (41). We in-
spected the sequencing reads of this variant to test whether the
deleterious allele was skewed towards homozygosity and found
that of the sequencing reads overlapping this variant position,
46 supported the alternate alleles, whereas only 28 supported
the reference allele, suggesting that the alternate allele is homo-
zygous in themosaic cell line. Nevertheless, this gene has not pre-
viously been implicated in DD; therefore, a deﬁnitive relationship
between this variant and the phenotype in the child was difﬁcult
to assess, and the variant as considered possibly pathogenic.
Patient 259029 was born at 40-week gestation with a birth
weight of 3.3 kg (41st centile). The child has dysmorphic facies in-
cluding severe hypertelorism, and clinical testing for craniofron-
tonasal dysplasia was negative. Our aCGH on saliva was not
obviously deviated. Our mosaic analysis detected a low-clonality
(23%) 3-Mb mosaic event on chromosome 11, with a small eleva-
tion of LRR (0.09). Intellectual disability and hypertelorism are
shared phenotypes with patient 255428 in the Decipher database
with an overlapping duplication. This region contains ALX4, a
gene implicated in skull ossiﬁcation defects, which may be con-
sistent with hypertelorism (42). However, this region has not
been consistently identiﬁed with other speciﬁc phenotypic fea-
tures in the child, and therefore, the variant was considered pos-
sibly pathogenic.
Discussion
The main aim of this study was to investigate whether children
withDDhave a signiﬁcant burden ofmosaic structural abnormal-
ities relative to age-matched controls. We estimated a ∼40-fold
enrichment of mosaicism in cases compared with controls.
Using single-sample and trio-based approaches, we calculated
that 0.9% of DDD probands had large-scale mosaicism. The sub-
stantial burden in cases suggests thatmany of these events were
pathogenic. We assessed whether the phenotypes in each child
were consistent with the mosaic mutations and concluded that
10 of 12 were highly likely to be pathogenic.
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One component of this study explored the relative perform-
ance of single-sample versus trio-based mosaic detection meth-
ods. Both methods discovered a majority of the total detections,
and neither software tool was clearly advantageous compared
with the other. triPOD identiﬁed two events of lower clonality
not found by MAD. While MAD has diminished sensitivity to
low-clonality events, it does not require complete trio data, a re-
source not always available; in this analysis, two real mosaic
events detected by MAD lacked complete trio data and were not
analysed by triPOD. Also, one third-haplotype gainwas not found
by triPOD, and the false-positive rate of triPOD was higher than
MAD. These ﬁndings suggest that employing either tool can
identify themajority ofmosaic events but thatmaximal sensitiv-
ity can be gained by leveraging the complementary strategies of
both tools if trio data are available.
Assessing the pathogenicity ofmosaic copy number and copy
neutral events requires several assumptions, primarily, that
events present inmosaic form cause phenotypes similar in char-
acter, if perhaps less severe, than events present in constitutive
form. We used this assumption when assessing pathogenicity
of the mosaic events. The majority of events detected were
copy number variablemosaicism,which is consistentwith previ-
ous studies, such as Conlin et al. (17). However, in contrast to the
study of mosaic aneuploidy, we found much lower levels of sex
chromosome aneuploidy (0 in 1303, compared with 9 of 2019),
and only a single event in our study was whole chromosome in
size. This may be due to differences in ascertainment, as ∼80%
of DDD probands were pre-screened by clinical aCGH testing,
which would have high sensitivity to detect chromosome-size
CNVs present in amajority of cells. In addition, sex chromosomal
aneuploidy results in distinctive phenotypes, which are likely
trigger extensive genetic investigations; this may compound
the bias against recruiting such patients to a research study fo-
cusing on undiagnosed patients. For these reasons, our estimate
of mosaic frequency in children with undiagnosed disorders is
likely an underestimate of frequency among all childrenwith DD.
Mosaic copy number events were typically not detected by
standard array CGH analysis. The detection of mosaicism re-
quires both the event to be present in the assayed tissue and sen-
sitive methods that are tailored to identify minimal skews in
either intensity, or allele fraction. No large mosaic copy number
events were identiﬁed in healthy controls, supporting prior evi-
dence that large copy number events are highly pathogenic. On
the other hand, one LOH type, a category of mutation impercept-
ible by aCGH, was detected in healthy controls. While constitu-
tive LOH has been identiﬁed in 1–1.5% of children with DD
(43,44), a signiﬁcant burden compared with the population level
rate (1 in 3500), the cases studied here did not have a statistically
signiﬁcant enrichment of LOH mosaicism (P > 0.05). It remains to
be seen whether with increased sample sizes, a burden may be-
come apparent, especially with respect to chromosomes sensi-
tive to imprinting disorders.
Theﬁltering strategy used to identify structuralmosaic events
was tuned to identify large (2Mb or larger) mosaicism, a size that
allowed fair comparison across data sets given the variability in
SNP density. Intuitively, larger events are more likely to be asso-
ciated with pathogenicity, and empirical observation demon-
strates that larger constitutive CNVs are rarely found in healthy
children (45). More powerful genetic assays, such as high-depth
whole-genome sequencing, will enable a higher-resolution com-
parison ofmosaic events at smaller sizes and allow improved de-
tection of pathogenic mosaicism (2).
The strategy of using inherited duplications to characterize
BAF and LRR properties of constitutive duplications for exclusion
of putative detectionswith similar BAFandLRRproﬁlesmayhave
inadvertently ﬁltered some mosaic duplications of very high
clonality. As the TEDS data set had SNP data with a higher
noise level compared with DDD, this effect may have been
more pronounced in the TEDS analysis, which could potentially
result in an underestimate of mosaicism in this control group.
Nevertheless, the data quality from TEDSwas sufﬁcient to detect
the size and clonality of mosaic events that were detected in the
other cohorts.
The SNP data in the DDD study were derived by salivary DNA
extraction. While salivary sampling is non-invasive and repre-
sents amixture of two tissue types (epidermvia buccal tissue epi-
thelium and mesoderm via lymphocytes) (46), this may have
limited our sensitivity to low-clonality events conﬁned to a single
tissue type. Because ALSPAC and TEDS data were derived from
only one tissue type (blood) and the distribution ofmosaic events
may differ across tissue types, it is possible that our frequency
comparison of mosaicism between cases and controls may
have been partially confounded by hidden stratiﬁcation, and in-
deed some mosaic abnormalities (such as the 12p tetrasomy
leading to Pallister–Killian syndrome) are rarely detected in
blood; however, the ﬁnding that the majority (6 of 8) of mosaic
events in saliva were also detected in blood suggests that this
effect may be minimal. In addition, this may provide some evi-
dence that mosaicism underlying DDs need not propagate into
all germ layers to result in syndromic dysfunction. However,
our assessment of tissue distribution was limited, as we did not
have access to endoderm-derived tissue, and factors that hinder
the extrapolation of germ layer distribution from assayed tissue
distribution, such as purifying selection against deleterious mo-
saicism and sampling error, may have played a role.
Detection of mosaicism in probands and subsequent genetic
diagnosis offers reassurances to parents that a subsequent child
is not at increased risk of developing the same mutation. Never-
theless, the majority of children with previously undiagnosed
genetic disorders still receive no genetic diagnosis after extensive
interrogation, including aCGH, exome and SNP-based analyses.
Improved detection of all forms of mosaicism is needed, includ-
ing smaller mosaic abnormalities, such as indels and point
mutations. This will require further reductions in sequencing
cost and the development of accurate sequence-based mosai-
cism detection algorithms.
Materials and Methods
Description of studies
The DDD Study is a parent-offspring trio study with a main ob-
jective of identifying the disease-causing variants in a sampling
of 12 000 children with undiagnosed severe developmental con-
ditions. The Scottish Family Health study is also a trio study, de-
signed to study the genetics of complex traits. Both the DDD and
SFHS cohorts were processed on the same custom Illumina® SNP
genotyping chip, a design combining 733 059 HumanOmni-
Express-12v1_A-b37 positions and 94 840 additional selected po-
sitions. DNA was sourced from saliva using Oragene® OG-500
(parent) or OG-575 (child) collection tubes (DNA Genotek, Inc.).
Genotyping was performed using Illuminus (47), recorded in
PLINK format (48) and converted to VCF format (49) using plink-
seq version 0.08. Probe-level quality control measures selected
polymorphic, well-covered positions that were absent from
copy number regions of at least 1% frequency (as calculated
from a composite of multiple CNV studies) (50,51). This resulted
in 679 891 assayed positions (SupplementaryMaterial, SNP probe
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selection). Samples were not excluded on outlier levels of BAFs or
LRRs because large (especially genome wide) mosaicism will
skew thesemeasures andwewanted to prevent unintentional ﬁl-
tering of realmosaicism. The SFHS set is a trio study composed of
young adults who lacked delays in development and is consid-
ered here as a control study without phenotypic selection.
We collected SNP data from two prospective, longitudinal,
birth cohort studies: TEDS and ALSPAC. The child participants
from Avon Longitudinal Study of Parents and Children (ALSPAC),
a cohort called ‘Children of the 90s’, consists of ∼15 000 children.
Illumina SNP genotyping was available for 8970 unique samples.
BAF and LRRmetrics were derived from raw data using published
guidelines (52) (Supplementary Material, : ALSPAC LRR and BAF
derivation). For 5667 samples, DNA was sourced from cell line
material, 3290 from blood or tissue and 13 had unknown origin.
The SNP genotyping chip assayed 478 184 sites on autosomes
and chromosome X aligning to GRCh19 and absent from copy
number regions of at least 1% frequency. Samples were excluded
from selection as controls if the child had phenotypes suggesting
developmental problems. Samples were excluded from the con-
trol cohort if either of the following phenotype exclusion criteria
were met: (sa032a) child has ever had developmental delay: yes;
(kd075) [parent] worries over development (kd705) above zero.
The ALSPAC study website contains details of all the data that
are available through a fully searchable data dictionary: http://
www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/.
Ethical approval for the study was obtained from the ALSPAC
Ethics and Law Committee and the Local Research Ethics
Committees.
The TEDS includes ∼13 000 unrelated twin pairs from England
and Wales. A main aim of the study is the investigation of genes
and environment on cognitive and behavioural development in
children. SNP genotype datawere derived from buccal swab sam-
pling using Affymetrix 6® chips. This genotyping chip assayed
695 017 sites on autosomes and chromosome X aligning to
GRCh19 and absent from common copy number regions (Supple-
mentary Material, SNP Probe Selection). Samples were excluded
from selection as controls if the child had phenotypes suggesting
perinatal or developmental problems at 4 years were noted: peri-
natal outlier overall exclusion ‘YES’, medical exclusion ‘YES’,
talking problem (dhtalk1) ‘YES’ or above 90th centile for total
behaviour problems (dbhbeht1 and dsdbeht1).
Mosaic event detection and ﬁltering strategies
We implemented two software packages for detection of mosaic
events from SNP genotyping data: (1) MAD, which detects a mo-
saic segment in a single sample as a genomic region with a con-
sistent skew in BAFs (12) and (2) triPOD, which detects a mosaic
segment in a proband of a patient–mother–father trio as a gen-
omic region of proband BAFs inconsistent with parental geno-
types (13). The advantage of triPOD is an increased sensitivity
compared with MAD for detecting events of low clonality; how-
ever, triPOD additionally requires parental genotype data,
which are not available in all studies.
MAD identiﬁes mosaic segments as clusters of B allele fre-
quencies (BAFs) with a similar skew statistically unlikely to be
from constitutive frequencies, where expected BAFs for AA, AB
and BB genotypes correspond to 0.0, 0.5 and 1.0 allele frequency.
Pertinent attributes of MAD-predicted events include the start
and end coordinates, and the average LRR and degree of BAF
skew from expectation (‘B-deviation’). Log R Ratio is used to clas-
sify the mosaic event by type (loss, gain or loss-of-heterozygos-
ity), whereas B-deviation is useful to assess the proportion of
assayed cells with the mosaic event. The following default par-
ameter values were used: aAlpha = 0.8, T = 9, MinSegLen = 75.
We implemented MAD for all samples from all cohorts.
Initial testing on all 5103 DDD and SFHS samples produced
2299 mosaic putative detections. This is several hundred times
higher than the expected number and manual inspection
of a large subset identiﬁed several sources of technical error,
most notably (1) hypersegmentation, (2) segments with skewing
of unimodal heterozygous BAFs and (3) segments of constitutive
regions of homozygosity and no heterozygous genotypes. We
developed a computational strategy to mitigate these errors
through automated ﬁltering. First, we managed hypersegmenta-
tion by merging nearby (within 1Mb) segments representing
the same event type (loss, gain or LOH) and averaged LRR and B
deviation among pre-merged fragments for themerged segment.
Segments beyond 2Mb in size after merging were retained.
The next step of the ﬁltering strategy implemented a peak-calling
strategy to distinguish between segments with bimodal BAF
clusters, segments with skewed unimodal BAF deviations
and constitutive regions of homozygosity (Supplementary
Material, Computational Filtering). This computational ﬁltering
strategy reduced the number of putatively mosaic segments en-
tering manual curation in the combined DDD and SHFS cohorts
by ∼90%.
In addition toMAD, triPODwas used to scrutinize detection of
low-clonality events. Default settings (alpha = 0.1, nc_thresh =
0.03) were used, except for genome build, which was changed
to ‘hg19’. All putative detections of at least 5Mb were manually
reviewed. There were ∼1000 putative detections at 2 Mb, and
∼200 events were reviewed, which identiﬁed 2 error modes: no
deﬂection in BAFs (spurious) and CNV present in parent (inher-
ited). Owing to the large number of detections, and our rationale
to use triPODmainly for the detection of low-clonality events, we
implemented computational ﬁltering to select segments at least
2Mb and had median BAFs of <0.70. We also observed several
hundred events with BAF values of ‘NA’ or 0.50 (no BAF shift),
which appeared spurious, so we implemented a 0.51 minimum
threshold cut-off. triPOD identiﬁed 11 events with highly skewed
BAFs and LRRs that were suggestive of inherited CNVs, and 10 of
11 CNVs were also present in a parent, substantiating the consti-
tutive nature of the event and that the event was inherited and
therefore not mosaic, whereas the remaining event clustered
with the inherited events was considered likely constitutive.
Genotypic–phenotypic workup
Each Decipher child enrolled in the DDD study was examined
by a clinical geneticist. The patient encounter included detailed
family history, prenatal, perinatal and the neonatal period.
Assessment of development milestones was performed, and
phenotypic features were recorded in Human Phenotype On-
tology format (HPO format). In addition, clinical photographs
were uploaded with parental consent (24, in review). Mosaic
events were assessed for pathogenicity using genomic disorder
databases, and exome sequence analysis was reviewed by a
multidisciplinary team of molecular scientists and Clinical
Geneticists.
The mosaic events of copy number type were assessed for
overlap with known genomic disorders. Each region was cross-
referenced with Decipher syndromic GRCh37 regions, and
OMIM morbid map (http://www.omim.org/). Genomic disorders
caused by CNVs of the same direction (losses or gains) were se-
lected. For LOH events, the exomes were interrogated for rare
variants genotyped as heterozygous or homozygous in these
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regions. Exome sequencing was performed as fully described
elsewhere (53). In brief, the exome capture design was Agilent®
SureSelect v.3 50-Mb baits and augmented with 5Mb of custom
regulatory sequences. Sequencing was performed using Illumi-
na® HiSeq 2000 platform to greater than 50× mean coverage
using paired-end 75-bp read-length sequence reads. Alignment
to the genome reference GRCh37, version hs37d, used bwa (54)
version 0.5.9. Quality control ﬁlters (genotype quality <30.0,
homopolymer runs >5, variant quality by depth <5.0, read
depth <4 or >1200 and strand bias >10.0) were applied.
Supplementary Material
Supplementary Material is available at HMG online.
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